Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adebrelimab + VEX metronomic chemotherapy
- Development stage
- Phase 2
- Lead developer
- Hengrui Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Adebrelimab + VEX metronomic chemotherapy is an investigational combination regimen consisting of the PD-L1 inhibitor adebrelimab and a metronomic chemotherapy schedule of oral vinorelbine, cyclophosphamide, and capecitabine (VEX). Adebrelimab is a humanized IgG4 monoclonal antibody that blocks the interaction between PD-L1 and its receptors PD-1 and B7.1, thereby restoring anti-tumor immune responses. The VEX regimen utilizes low-dose, frequent administration of cytotoxic agents to exert anti-angiogenic and immunomodulatory effects while minimizing toxicity compared to standard bolus dosing. This combination is primarily being evaluated in Phase II clinical trials for the treatment of advanced triple-negative breast cancer (TNBC), often in conjunction with radiotherapy, to improve clinical outcomes in patients with limited treatment options.
- Brand names
- Adebry
- Other names
- adebrelimab + VEXadebrelimab + vinorelbine + cyclophosphamide + capecitabine
02
Targets
DNACD274 (Programmed cell death protein 1 ligand 1)TS (Thymidylate synthase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on adebrelimab + VEX metronomic chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adebrelimab + VEX metronomic chemotherapy.